-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 29, 2021, Ranok Therapeutics announced an agreement with Pfizer to use the company’s proprietary molecular chaperone-mediated targeted protein degradation (CHAMP) technology platform to target an undisclosed Of cancer targets to develop innovative therapies
In recent years, targeted protein degradation has become a new direction in the development of small molecule drugs
In some cases, the chaperone can bind to E3 ubiquitin ligase and mediate the degradation of the substrate by the proteasome
▲Principle of CHAMP technology platform (picture source: Shunuo Biological official website)
Through this platform, Pinnacle Biosciences develops innovative drugs needed for tumors and other major diseases, improves the long-term quality of life of patients, and satisfies unmet clinical needs.
Reference materials:
[1] Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation.